Dr Milène Volpato
- Position: Lecturer in Cancer Pharmacology, FHEA
- Areas of expertise: Cancer pharmacology; Translational cancer research; Omega-3 fatty acids; Colorectal cancer
- Email: M.Volpato@leeds.ac.uk
- Phone: +44(0)113 343 8423
- Location: Wellcome Trust Brenner Building
- Website: Researchgate | ORCID
I did my undergraduate studies at the University Paul Sabatier in Toulouse, France. I came to the UK in 2001, at the Institute of Cancer Therapeutics, University of Bradford, where I obtained my PhD in Cancer Pharmacology, on the preclinical development of novel NQO1 targeting pro-drugs and predictive biomarkers of response in superficial bladder cancer, working with Professor Roger Phillips and Professor Paul Loadman.
I then worked on the genetic epidemiology of NQO1 polymorphisms in cervical cancer and their impact on tumour development and progression in the context of Human Papilloma Virus infection. I joined the laboratory of Professor TH. Rabbitts ( FRS) in Leeds, where I studied the molecular basis of lineage reassignment and leukemogenesis upon chromosomal translocation within in vivo MLL-related leukaemia models. I joined Professor Mark Hull and the Molecular Gastroenterology group in 2010. My research has since focused on the preclinical development of omega-3 polyunsaturated fatty acids, eicosapentaenoic acid (EPA) in particular, for the prevention and/or treatment of colorectal cancer.
- Programme Lead, MSc Cancer Biology and Therapy
- Academic sub-dean for postgraduate assessment, School of Medicine
- Academic Adviser to the Commonwealth Scholarship Commission
My work is centred on the pre-clinical development of the naturally occurring omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), for the prevention and treatment of colorectal cancer. I work with a range of pre-clinical models to investigate potential mechanisms of resistance to the omega-3 fatty acids in colorectal cancer in order to personalise therapy and develop a combination regimen to improve patient outcomes. In particular, I am investigating how EPA and DHA can enhance tumour response to a range of immunotherapies, including immune checkpoint inhibitor and oncolytic virus in a range of solid tumours.
Miss Nametso Khumo
Miss Isata Fofanah
Mr John Hutchinson
Miss Catriona Marshall
- PhD Cancer Pharmacology, UK
- MSc in Health Bioengineering, France
- UK Therapeutic Cancer Prevention Network
I am a LPGR for posgraduates stduents in LIMR
I delivermodules for the MSc Molecular Medicine and MSc Cancer Biology and Therapy (School of Medicine), on laboratory research and cancer drug development
I am the programme lead for MSc Cancer Biology and Therapy and the Deputy Lead for MSc Molecular Medicine
I supervise BSc, MSc and FY2 medical students during their research projects, as well as PhD students.
Research groups and institutes
- Leeds Institute of Medical Research at St James's
<li><a href="//phd.leeds.ac.uk/project/1485-cancer:-complex-3d-modelling-of-the-tumour-microenvironment-for-immunotherapy-combination-screening">Cancer: Complex 3D modelling of the tumour microenvironment for immunotherapy combination screening</a></li>
<li><a href="//phd.leeds.ac.uk/project/1503-translational-medicine:-understanding-the-mechanism(s)-of-resistance-to-epa-to-personalise-therapy-and-improve-outcome">Translational Medicine: Understanding the mechanism(s) of resistance to EPA to personalise therapy and improve outcome</a></li>